THE CHALLENGE - A leading biotechnology company approached Frost & Sullivan in order to understand the impact of Medicare reimbursement policy on Biological Response Modifiers (BRMs) in Rheumatoid Arthritis markets. In addition, the company was interested in determining the appropriate methods for improving its market share in the highly competitive pharmaceutical and clinical diagnostics marketplace.

THE PROCESS - In order to meet this challenge, Frost & Sullivan leveraged its experienced market research and consulting team that consistently track BRMs and the Rheumatoid Arthritis market. Because of its expertise, the team is fully capable of understanding the Medicare policy and its impact on BRM markets. The group identified and contacted key market participants and insurance companies, including Medicare, to develop a comprehensive outlook on the impact of the new law on each BRM.

THE SOLUTION - As a result of the analysis, the client was better equipped to develop a new
BRM formulation that was reimbursable and improved both physician and patient acceptance. In addition, the company leveraged Frost & Sullivan's industry data to develop market strategies for succeeding in the competitive marketplace.